C. Haioun

Articles

Rituximab Plus CHOP in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: An Update of the GELA Study

Bertrand Coiffier, MD, PhD;C. Fermé;Olivier Hermine, MD, PhD;C. Haioun;E. Baumelou;P. Solal-Celigny;A. Delmer;C. Sebban;N. Mounier;G. Tertian;A. Van Hoof;A. Bosly

March 1st 2002

At the 2000 Annual Meeting of the American Society of Hematology, we presented the benefits of rituximab (Rituxan) combined with CHOP (cyclophosphamide [Cytoxan, Neosar], doxorubicin HCl, vincristine [Oncovin], prednisone), known as R-CHOP, in comparison with CHOP alone for the treatment of elderly patients with diffuse large B-cell lymphoma (DLCL).

Efficiency of In Vivo Purging With Rituximab Followed by High-Dose Therapy With Autologous Peripheral Blood Stem Cell Transplantation in B-Cell Non-Hodgkin’s Lymphomas: A Single-Institution Study

C. Haioun;M. H. Delfau-Larue;F. Beaujean;J. L. Beaumont;K. Belhadj;C. Pautas;Y. Kirova;A. Allain;P. Gaulard;J. P. Farcet;Felix Reyes, MD

March 1st 2001

High-dose therapy (HDT) with peripheral blood stem cell transplantation is a treatment option for patients with advanced follicular, marginal, and mantle cell lymphoma. In this setting, frequent contamination of peripheral blood stem cell harvests by